课题基金 / 基金详情

DIRECT EFFECTS OF PIOGLITAZONE ON GLUCONEOGENESIS IN TYPE II DIABETES

DIRECT EFFECTS OF PIOGLITAZONE ON GLUCONEOGENESIS IN TYPE II DIABETES
吡格列酮对 II 型糖尿病糖异生的直接影响
批准号：
6306599
负责人：
JOHN A TAYEK
金额：
$0.1万
依托单位：
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
1999
资助国家：
美国
项目状态：
已结题
起止时间：
1999-12-01 至 2000-11-30
来源：
https://reporter.nih.gov/project-details/6306599
关键词：
clinical research drug screening /evaluation gluconeogenesis glucose metabolism human subject human therapy evaluation hypoglycemic agents leucine noninsulin dependent diabetes mellitus oxidation protein metabolism

项目摘要

项目成果

JOHN A TAYEK的其他基金

相关文献

中文摘要
翻译
II型糖尿病与肝糖释放增加30% - 70%有关。这会提高空腹血糖。本研究将研究一种新的糖尿病药物对正常和II型糖尿病患者糖异生和蛋白质分解代谢的直接影响。众所周知，糖尿病患者的糖异生率和亮氨酸氧化率升高。这种新药物已知能减少葡萄糖从肝脏释放，但不知道它是否能减少糖异生、糖原分解或亮氨酸氧化。”
英文摘要
Type II diabetes is associated with a 30 to 70% increase in liver glucose relea- se. This raises fasting blood glucose. This research will study the direct eff- ect of a new diabetic medication on gluconeogenesis and protein catabolism in normals and in type II diabetes. Diabetics are known to have an elevated rate of gluconeogenesis and an elevated rate of leucine oxidation. This new medication is known to reduce glucose release from the liver, but it is not known if it is decreasing gluconeogenesis, glycogen breakdown, or leucine oxidation."
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Arginine Treatment for Alcoholic Hepatitis
Arginine Treatment for Alcoholic Hepatitis
Arginine Treatment for Alcoholic Hepatitis
ABNORMAL GLUCONEOGENESIS IN TYPE II DIABETES